Arovella Therapeutics Ltd (ASX:ALA) has received a $3 million research and development (R&D) rebate from the Federal government for its work in developing a cancer-treating cell therapy, with a further $0.3 million expected in the coming months. The latter amount relates to eligible expenditure which was actually covered by an overseas finding received after Arovella lodged its income tax return (which had yielded the $3M refund). The total cash will enable the company to push ahead with plans to get its main asset ALA-101 – a cell therapy aimed at treating blood cancers and solid tumours – in…